IMVT Immunovant, Inc.

CIK 0001764013 50 ready 8-Ks latest May 20, 2026, 7:14 AM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing May 20, 2026, 7:14 AM ET

Top materiality 0.90

Event mix other_material ×25 · earnings ×16 · other ×5

Sentiment 16 pos · 2 neg · 32 neu

Latest earnings reported 2026-Q3

Executive change recent →

Recent 8-K filings for IMVT

Highest-materiality recent filing

Immunovant reports ~80% response and 50% ATD-free remission in Graves' disease trial at six months off-treatment

September 3, 2025, 7:59 PM ET other material materiality 0.90 positive item 7.01 item 8.01 item 9.01

80% (17/21) of uncontrolled Graves' patients maintained normal thyroid function six months after stopping batoclimab.
50% (8/17) of responders achieved anti-thyroid drug-free remission at six months off-treatment.

Read filing →

May 20, 2026, 7:14 AM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Immunovant posts $0.73/sh Q4 loss; IMVT-1402 hits 72.7% ACR20 in D2T RA at Week 16

IMVT-1402 in D2T RA: 72.7% ACR20, 54.5% ACR50, 35.8% ACR70 at Week 16; open-label, blinded assessors; safety well-tolerated.
February 6, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Immunovant reports Q3 net loss of $110.6M; cash $994.5M; D2T RA trial fully enrolled

Net loss $110.6M ($0.61/sh) for Q3 FY26; non-GAAP net loss $97.5M.
December 12, 2025, 6:59 PM ET other material materiality 0.70 neutral item 8.01 item 9.01

Immunovant raises $550M via 26.2M share offering at $21.00/share

Gross proceeds ~$550M from 26.2M shares priced at $21.00/share.
December 11, 2025, 6:59 PM ET other material materiality 0.70 negative item 8.01

Immunovant prices $550M stock offering; updates IMVT-1402 and batoclimab timelines

Underwritten common stock offering of ~$550M gross proceeds; Roivant Sciences to purchase shares; expected close Dec 12, 2025.
November 21, 2025, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

Immunovant CMO Michael Geffner departs; consulting through April 2026

Michael Geffner, M.D., M.B.A., ceased as Chief Medical Officer effective Nov 21, 2025.
November 10, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Immunovant Q2 loss $126.5M; batoclimab TED readout delayed to H1 2026; cash $521.9M

Net loss $126.5M ($0.73/share) in fiscal Q2 ended Sep 30, 2025, vs $109.1M ($0.74) prior year.
September 3, 2025, 7:59 PM ET other material materiality 0.90 positive item 7.01 item 8.01 item 9.01

Immunovant reports ~80% response and 50% ATD-free remission in Graves' disease trial at six months off-treatment

80% (17/21) of uncontrolled Graves' patients maintained normal thyroid function six months after stopping batoclimab.
August 28, 2025, 7:59 PM ET other materiality 0.10 neutral item 5.07

Immunovant shareholders elect all three director nominees, ratify auditor, approve say-on-pay

Jacob Bauer, Douglas Hughes, and Robert Susman elected to Board until 2026 annual meeting.
August 11, 2025, 7:59 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01

Immunovant Q1 net loss $120.6M; initiates two registrational trials for IMVT-1402

Cash of $598.9M provides runway through Graves' disease readout expected in 2027.
July 29, 2025, 7:59 PM ET leadership materiality 0.55 neutral item 5.02

Immunovant finalizes CEO Eric Venker's employment agreement with $672K salary, equity awards

Annual base salary $672,000; target annual bonus 72.25% of base salary.
May 29, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01

Immunovant Q4 FY2025 net loss $106.4M, cash $714M; new CEO Eric Venker

Net loss of $106.4M ($0.64/share) for Q4 FY2025, vs $75.3M ($0.52/share) a year ago.
April 21, 2025, 7:59 PM ET leadership materiality 0.80 positive item 5.02 item 7.01 item 8.01 item 9.01 ◈ executive_change ×6

Immunovant appoints new CEO/CFO, expands IMVT-1402 into Sjögren's and CLE

CEO Peter Salzmann retired; Eric Venker (Roivant President) appointed CEO, effective April 21.
March 19, 2025, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Batoclimab meets MG Phase 3 primary endpoint; CIDP shows 84% responder rate with >70% IgG reduction

MG Phase 3: 680mg batoclimab arm achieved 5.6-point MG-ADL improvement vs 3.6 placebo (p<0.001).
February 6, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 9.01

Immunovant reports Q3 net loss $111.1M; cash $374.7M plus $450M placement

Net loss $111.1M ($0.76/sh) vs $51.4M ($0.36) y/y; R&D spend $94.5M up from $48.3M on IMVT-1402 prep.
January 24, 2025, 6:59 PM ET other material materiality 0.20 neutral item 8.01 item 9.01

Immunovant files prospectus supplement to register 5.65M shares for resale by selling stockholders

Filed prospectus supplement to register up to 5,654,990 shares of common stock for resale by selling stockholders.
January 14, 2025, 6:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Immunovant presents corporate overview at J.P. Morgan Healthcare Conference; no new data disclosed

Presentation on January 14, 2025 covers autoimmune pipeline and tailored science approach.
January 13, 2025, 6:59 PM ET other material materiality 0.75 positive item 1.01 item 3.02 item 7.01 item 9.01

Immunovant announces $450M PIPE at $20/share to advance pipeline

Agreed to sell 22.5M shares at $20/share to three institutional investors, including Roivant Sciences.
November 7, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02 item 8.01 item 9.01

Immunovant announces five IND clearances for IMVT-1402 and plans to initiate registrational trials by March 2025

Five INDs cleared for IMVT-1402 across therapeutic areas including Graves' disease and rheumatoid arthritis.
September 9, 2024, 7:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Immunovant reports 76% response rate in Graves' Disease Phase 2a; IND cleared for IMVT-1402 pivotal trial

High-dose batoclimab (680 mg SC weekly) achieved 76% response rate and 56% ATD-free response at week 12 in patients uncontrolled on antithyroid drugs.
August 13, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07

Immunovant stockholders elect directors, ratify auditor, approve compensation at 2024 annual meeting

Three directors (Salzmann, Migausky, Hughes) elected with over 97M votes for each, ~6.5M broker non-votes.
August 6, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Immunovant reports Q1 FY2025 net loss $87.2M; completes batoclimab MG enrollment

Net loss $87.2M ($0.60/share) vs $73.9M ($0.57) YoY; cash $560M as of June 30, 2024.
May 29, 2024, 7:59 PM ET earnings materiality 0.85 neutral item 2.02 item 9.01

Immunovant reports Q4 net loss $75.3M, cash $635M; plans 4-5 registrational IMVT-1402 studies by 2025

Net loss $75.3M ($0.52/sh) for Q4 FY2024 vs $59.4M ($0.46/sh) YoY; FY net loss $259.3M ($1.88/sh).
February 12, 2024, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Immunovant reports Q3 net loss $51.4M; plans 4-5 registrational trials for IMVT-1402

Net loss of $51.4M ($0.36/share) vs $63.2M ($0.49) a year ago; cash & equivalents $691M.
January 9, 2024, 6:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

Immunovant corporate presentation at J.P. Morgan Healthcare Conference; no specific details disclosed

Immunovant presented a corporate overview at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024.
December 20, 2023, 6:59 PM ET other material materiality 0.75 positive item 7.01 item 8.01 item 9.01

Immunovant reports positive initial Phase 2 data for batoclimab in Graves' disease; IgG reduction up to 87%

Initial cohort in Phase 2 trial exceeded 50% response rate; response defined as normalization of T3/T4 without increasing ATD dose.
November 28, 2023, 6:59 PM ET other material materiality 0.70 positive item 7.01 item 8.01 item 9.01

Immunovant reports positive IMVT-1402 600 mg Phase 1 data: 74% IgG reduction, placebo-like albumin/LDL-C

Four weekly 600 mg SC doses of IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% at 680 mg.
November 9, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

Immunovant reports Q2 FY2024 net loss of $58.7M; Phase 1 data supports IMVT-1402 best-in-class potential

Net loss of $58.7M ($0.45/share) for Sep Q, vs. $47.9M ($0.41) a year ago; wider loss on higher R&D.
September 28, 2023, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 9.01 ◈ Material Agreements ×2

Immunovant Prices $280M Public Offering; Roivant Commits $170M Private Placement

Public offering of 7,370,000 shares at $38.00/share; gross proceeds ~$280.1M.
September 26, 2023, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Immunovant announces positive initial Phase 1 data for IMVT-1402 with IgG reductions and no albumin or LDL-C changes

Mean total IgG reduction of 63% after four weekly 300 mg SC doses of IMVT-1402 in Phase 1 MAD cohort.
August 23, 2023, 7:59 PM ET other materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×3

Immunovant shareholders elect three directors, ratify EY, approve exec compensation

Peter Salzmann (98.5M for, 17.7M withheld), Douglas Hughes (96.6M for, 19.6M withheld), George Migausky (96.6M for, 19.7M withheld) elected to board.
August 10, 2023, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01 ◈ Earnings Releases

Immunovant reports Q1 net loss of $73.9M; IMVT-1402 Phase 1 data on track for September 2023

Net loss $73.9M ($0.57/share) vs $40.4M ($0.35/share) in prior year; cash $330M funds ops into H2 2025.
May 22, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 8.01 item 9.01 ◈ Earnings Releases ×2

Immunovant reports FY2023 net loss $211M; IMVT-1402 IND cleared, Phase 1 started

Net loss of $59.4M ($0.46/share) for Q4 FY2023 vs $47.2M ($0.41) a year ago.
March 27, 2023, 7:59 PM ET other material materiality 0.20 neutral item 8.01 item 9.01

Immunovant files 8-K with corporate presentation; no material updates disclosed in filing or exhibit text.

Immunovant released a new corporate presentation for investor business updates on March 27, 2023.
February 3, 2023, 6:59 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01 ◈ Earnings Releases ×2

Immunovant reports widened Q3 net loss of $63.2M; cash $432.6M; batoclimab trials on track

Net loss $63.2M ($0.49/share) vs $41.4M ($0.36) prior year; R&D spend rose to $42.3M.
January 9, 2023, 6:59 PM ET other material materiality 0.20 neutral item 8.01 item 9.01

Immunovant presents at J.P. Morgan Healthcare Conference with new corporate deck; no specific data disclosed

Presentation at 41st Annual J.P. Morgan Healthcare Conference beginning January 9, 2023.
December 8, 2022, 6:59 PM ET other materiality 0.20 neutral item 7.01 item 9.01

Immunovant presents at LifeSci Capital fireside chat; no material details disclosed

Immunovant participated in a virtual fireside chat hosted by LifeSci Capital on December 8, 2022.
November 4, 2022, 7:59 PM ET other material materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases

Immunovant unveils next-gen FcRn inhibitor IMVT-1402; Q2 net loss $47.9M

IMVT-1402 observed in animal study to have best-in-class IgG reduction with minimal albumin/LDL impact.
October 4, 2022, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 8.01 item 9.01

Immunovant prices $75M stock offering at $6/share to fund IMVT-1402 development

Priced 12.5M shares at $6.00 per share; gross proceeds ~$75M before discounts.
September 28, 2022, 7:59 PM ET other material materiality 0.80 positive item 7.01 item 8.01 item 9.01

Immunovant announces next-generation anti-FcRn IMVT-1402 with promising preclinical data

IMVT-1402 showed deep IgG lowering with minimal impact on albumin and LDL in animal studies.
September 7, 2022, 7:59 PM ET other material materiality 0.60 positive item 7.01 item 8.01 item 9.01

Immunovant to start pivotal Phase 2b in CIDP in H2 2022; Phase 2 in Graves' Disease in early 2023

Pivotal Phase 2b trial of batoclimab in CIDP to start H2 2022; initial open-label results expected H1 2024.
August 19, 2022, 7:59 PM ET other materiality 0.10 neutral item 5.07

Immunovant stockholders elect directors, ratify auditor, approve say-on-pay at 2022 annual meeting

Three directors elected: Peter Salzmann, Douglas Hughes, George Migausky — all with >90M votes for.
August 5, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Immunovant Q1 net loss $40.4M; initiates pivotal MG trial, TED trials on track

Net loss of $40.4M ($0.35/share) vs $30.5M ($0.31) YoY; R&D expenses up to $28.4M from $18.7M.
June 8, 2022, 7:59 PM ET other material materiality 0.75 positive item 2.02 item 7.01 item 9.01

Immunovant gains FDA alignment for Phase 3 batoclimab trials in TED; reports FY2022 loss of $156.7M

FDA aligned on Phase 3 TED program: two placebo-controlled trials (100 patients each) initiating H2 2022; top-line data H1 2025.
March 30, 2022, 7:59 PM ET other material materiality 0.30 neutral item 7.01 item 9.01

Immunovant R&D Day presentation filed; details not fully available in text

Immunovant hosted a virtual R&D Day on March 30, 2022; presentation filed as Exhibit 99.1.
February 4, 2022, 6:59 PM ET earnings materiality 0.55 negative item 2.02 item 9.01

Immunovant Q3 net loss widens to $41.4M; cash at $527M; clinical pause continues

Net loss of $41.4M ($0.36 per share) for Dec 2021 quarter vs. $31.8M ($0.32) a year ago.
January 7, 2022, 6:59 PM ET other materiality 0.20 neutral item 7.01 item 9.01

Immunovant to present corporate overview at J.P. Morgan Healthcare Conference on Jan 13, 2022

CEO Pete Salzmann to present on Thursday, January 13, 2022 at 9:45am ET.
January 5, 2022, 6:59 PM ET other material materiality 0.75 neutral item 7.01 item 9.01

Immunovant provides Phase 3 update for batoclimab in myasthenia gravis

Corporate webcast held Jan 5, 2022; presentation focuses on Phase 3 development of batoclimab.
December 30, 2021, 6:59 PM ET regulatory materiality 0.75 positive item 7.01 item 9.01

Immunovant achieves FDA alignment to start Phase 3 trial for batoclimab in MG in 1H 2022

FDA Division of Neurology 1 agreed to move forward; Phase 3 for batoclimab in myasthenia gravis starts 1H 2022.
November 23, 2021, 6:59 PM ET other material materiality 0.60 neutral item 1.01

Immunovant enters $36M manufacturing deal with Samsung Biologics for batoclimab

Minimum purchase commitment estimated at $36M; PSA runs through Dec 31, 2029.
November 17, 2021, 6:59 PM ET other material materiality 0.15 neutral item 7.01 item 9.01

Immunovant to present corporate overview at Stifel Virtual Healthcare Conference Nov 17

CEO Pete Salzmann to present at Stifel 2021 Virtual Healthcare Conference on Nov 17, 2021 at 2:00pm ET.

Executive changes

Departed

Peter Salzmann

Member of Board of Directors

IMVT · Immunovant, Inc.

Effective: 2025-04-18
Filed: April 21, 2025, 7:59 PM ET

and as a member of the Company’s Board of Directors (the “Board”), effective April 18, 2025.

Appointed

Robert Susman

Member of Board of Directors

IMVT · Immunovant, Inc.

Effective: 2025-04-18
Filed: April 21, 2025, 7:59 PM ET

the Board appointed Robert Susman and Jacob Bauer to fill the vacancies on the Board created by the departure of each of Dr. Salzmann and Mr. Migausky

Appointed

Jacob Bauer

Member of Board of Directors

IMVT · Immunovant, Inc.

Effective: 2025-04-18
Filed: April 21, 2025, 7:59 PM ET

the Board appointed Robert Susman and Jacob Bauer to fill the vacancies on the Board created by the departure of each of Dr. Salzmann and Mr. Migausky

Departed

Peter Salzmann

Chief Executive Officer

IMVT · Immunovant, Inc.

Effective: 2025-04-20
Successor: Eric Venker
Filed: April 21, 2025, 7:59 PM ET

Peter Salzmann, M.D. retired from his roles as the Chief Executive Officer and principal executive officer of Immunovant, Inc. (the "Company" or "Immunovant"), effective April 20, 2025

Departed

George Migausky

Member of Board of Directors

IMVT · Immunovant, Inc.

Effective: 2025-04-18
Filed: April 21, 2025, 7:59 PM ET

On April 18, 2025, George Migausky, a member of Immunovant’s Board and Chair of the Audit Committee of the Board (the “Audit Committee”), resigned from the Board and the Audit Committee, effective immediately.

Departed

Renee Barnett

Chief Financial Officer

IMVT · Immunovant, Inc.

Effective: 2025-04-20
Successor: Tiago Girao
Filed: April 21, 2025, 7:59 PM ET

Also effective April 20, 2025, Renee Barnett ceased serving as the Chief Financial Officer (including the principal financial officer and principal accounting officer) of the Company.

Appointed

Eric Venker

Director

IMVT · Immunovant, Inc.

Effective: 2021-09-09
Filed: September 15, 2021, 7:59 PM ET

Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant

Appointed

Atul Pande

Director

IMVT · Immunovant, Inc.

Effective: 2021-09-09
Filed: September 15, 2021, 7:59 PM ET

Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant

Appointed

Renee Barnett

Chief Financial Officer

IMVT · Immunovant, Inc.

Effective: 2021-10-04
Filed: September 15, 2021, 7:59 PM ET

On September 14, 2021, Renee Barnett was appointed the Chief Financial Officer of Immunovant, Inc. effective October 4, 2021.

Appointed

Andrew Fromkin

Director

IMVT · Immunovant, Inc.

Effective: 2021-09-09
Filed: September 15, 2021, 7:59 PM ET

Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant

Appointed

Frank M. Torti

Director

IMVT · Immunovant, Inc.

Effective: 2021-09-09
Filed: September 15, 2021, 7:59 PM ET

Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant

Appointed

Dr. Frank M. Torti

Executive Chairperson

IMVT · Immunovant, Inc.

Effective: 2021-08-02
Filed: August 2, 2021, 7:59 PM ET

Effective August 2, 2021, Dr. Frank M. Torti, age 42, Immunovant’s current Chairperson, was appointed Executive Chairperson.

Earnings & guidance

2026-Q3 EPS reported -$2.04 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.68 · Most common event other_material

16 positive 2 negative 32 neutral

source · IMVT on sec.gov